Lukas Bubendorf
0000-0001-5970-1803
Publication & Citation Trends
Publications
655 total
A Th17 signature correlates with response to dual CTLA-4 and PD-1 blockade in metastatic renal cell carcinoma
Cited by 0
Semantic Scholar
A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee PDF
Cited by 525
OpenAlex
Tumor mutational burden assessed by a targeted NGS assay to predict clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
Cited by 0
Semantic Scholar
ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib. OA
Cited by 11
Semantic Scholar
Computer-based intensity measurement assists pathologists in scoring PTEN immunohistochemistry - Clinical associations in NSCLC patients of the ETOP Lungscape cohort
Cited by 0
Semantic Scholar
159P Initial serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC
Cited by 0
Semantic Scholar
PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project PDF
Cited by 796
OpenAlex
[Molecular pathological diagnosis in cytopathology of non-small-cell lung cancer. Standardization of specimen processing].
Cited by 10
Semantic Scholar
Research Topics
Lung Cancer Treatments and Mutations
(155)
Prostate Cancer Treatment and Research
(126)
Cancer Genomics and Diagnostics
(125)
Bladder and Urothelial Cancer Treatments
(77)
Lung Cancer Diagnosis and Treatment
(57)
Affiliations
Università Cattolica del Sacro Cuore
University of Vermont
Roche (Switzerland)
University of Bern
Mount Sinai Hospital